We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current AKBA market cap is 410.14M. The company's latest EPS is USD -0.2380 and P/E is -7.69.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 42.05M | 56.2M | 32.61M | 43.65M | 37.43M |
| Operating Income | -13.04M | 1.37M | -14.94M | -8.72M | -12.51M |
| Net Income | -14.49M | 614k | -17.99M | -8.58M | -20.04M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 335M | 295.31M | 213.58M | 292.6M | 194.62M |
| Operating Income | -286.29M | -376.44M | -265.32M | -79.12M | -46.26M |
| Net Income | -279.66M | -383.46M | -282.84M | -92.56M | -51.93M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 235M | 241.7M | 225.48M | 220.2M | 207.14M |
| Total Liabilities | 274.42M | 272.29M | 252.74M | 253.95M | 257.54M |
| Total Equity | -39.42M | -30.58M | -27.26M | -33.75M | -50.4M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 771.2M | 644.14M | 525.55M | 351.83M | 241.7M |
| Total Liabilities | 376.44M | 396.52M | 449.09M | 342.49M | 272.29M |
| Total Equity | 394.76M | 247.62M | 76.46M | 9.34M | -30.58M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -21.08M | -23.38M | -19.43M | -29.5M | -36.19M |
| Investing | N/A | N/A | N/A | -29k | -31k |
| Financing | -23.92M | -25.21M | 18.48M | 26.12M | 27.34M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -257.44M | -110.39M | -252.97M | -73.15M | -23.38M |
| Investing | 211.18M | -40M | 39.94M | -114k | N/A |
| Financing | 88.97M | 231.72M | 133.73M | 14.6M | -25.21M |
| Market Cap | 410.14M |
| Price to Earnings Ratio | -7.69 |
| Price to Sales Ratio | 2.05 |
| Price to Cash Ratio | 9.3 |
| Price to Book Ratio | -13.05 |
| Dividend Yield | - |
| Shares Outstanding | 218.18M |
| Average Volume (1 week) | 1.84M |
| Average Volume (1 Month) | 2.11M |
| 52 Week Change | 56.65% |
| 52 Week High | 2.48 |
| 52 Week Low | 0.80 |
| Spread (Intraday) | 0.31 (14.76%) |
| Company Name | Akebia Therapeutics Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.akebia.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
